| 0 (0%) | 12-12 14:56 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 63.39 | 1-year : | 65.93 |
| Resists | First : | 54.27 | Second : | 56.45 |
| Pivot price | 54.32  |
|||
| Supports | First : | 50.75 | Second : | 42.23 |
| MAs | MA(5) : | 53.29  |
MA(20) : | 54.16 |
| MA(100) : | 55.28 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 19.9 |
D(3) : | 28.8 |
| RSI | RSI(14): 42.9 |
|||
| 52-week | High : | 73.51 | Low : | 50.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BMRN ] has closed above bottom band by 13.1%. Bollinger Bands are 3.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 54.43 - 54.74 | 54.74 - 55.08 |
| Low: | 52.03 - 52.37 | 52.37 - 52.74 |
| Close: | 52.36 - 52.95 | 52.95 - 53.59 |
Fri, 12 Dec 2025
BioMarin (BMRN): Has the Market Overreacted to This Year’s Pullback in a Profitable Rare-Disease Leader? - simplywall.st
Thu, 11 Dec 2025
Is The Market Mispricing BioMarin After Its Multi Year Share Price Slump In 2025 - Yahoo Finance
Thu, 11 Dec 2025
BioMarin Pharmaceutical (BMRN) Valuation Check After This Year’s 20% Share Price Pullback - Yahoo Finance
Thu, 11 Dec 2025
BioMarin Pharmaceutical (BMRN) Valuation Check After This Year’s 20% Share Price Pullback - Yahoo Finance UK
Thu, 11 Dec 2025
How Restructuring-Driven Margin Gains And Higher Guidance At BioMarin (BMRN) Have Changed Its Investment Story - Sahm
Thu, 11 Dec 2025
Leerink cuts BioMarin Pharmaceutical Inc. (BMRN) price target to $60, citing valuation and competitive challenges - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 192 (M) |
| Shares Float | 190 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 98 (%) |
| Shares Short | 8,950 (K) |
| Shares Short P.Month | 8,510 (K) |
| EPS | 2.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 31.53 |
| Profit Margin | 16.8 % |
| Operating Margin | -6.1 % |
| Return on Assets (ttm) | 6.1 % |
| Return on Equity (ttm) | 9 % |
| Qtrly Rev. Growth | 4 % |
| Gross Profit (p.s.) | 13.11 |
| Sales Per Share | 16.08 |
| EBITDA (p.s.) | 4.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 914 (M) |
| Levered Free Cash Flow | 452 (M) |
| PE Ratio | 19.6 |
| PEG Ratio | 0 |
| Price to Book value | 1.67 |
| Price to Sales | 3.27 |
| Price to Cash Flow | 11.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|